Servier, VCs invest $21 mln to create new Québec biotech startup
The Fonds de solidarité FTQ, CTI Life Sciences Fund and the Canadian affiliate of French pharmaceutical company Servier have invested $21 million to help launch a new biotechnology startup, Ilkos Therapeutics. Based in Laval, Québec, Ilkos will focus on the clinical development of an oral treatment for venous lower limb ulcers. Servier granted an exclusive licence to the company to pursue the project and will oversee it through Servier Canada's Centre of Excellence in Clinical Research. Ilkos' board will be chaired by Canadian healthcare executive Mark Beaudet. The Fonds' Danny Gagné, CTI's Jean-François Leprince, and Servier's Frédéric Fasano will take seats on the board.
26 September 2016•5 mins read
